Fondazione Oncotech Impresa Sociale

Fondazione Oncotech Impresa Sociale supports clinical research in ER-positive, HER2-negative breast cancer, with a particular focus on patients with early breast cancer and hormone receptor-positive disease. The funded studies concentrate on treatment strategies used before surgery and on clinical questions relevant to localized disease management.

• Neoadjuvant therapy in ER-positive, HER2-negative breast cancer
• Early-stage breast cancer
• Hormone receptor-positive disease

The sponsor’s research activity is centered on improving care in a defined breast oncology population through studies conducted at multiple collaborating sites in Italy.